Regulatoriskt pressmeddelande11.12.2025 klo 11.45Diagonal Bio intends to submit a formal application for bankruptcy
Regulatoriskt pressmeddelande31.10.2025 klo 09.00Diagonal Bio publishes interim report for the third quarter of 2025
Pressmeddelande13.10.2025 klo 10.00Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment
Pressmeddelande03.10.2025 klo 12.30Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses
Regulatoriskt pressmeddelande23.09.2025 klo 12.15Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2
Regulatoriskt pressmeddelande22.08.2025 klo 09.00Diagonal Bio publishes interim report for the second quarter of 2025
Pressmeddelande07.07.2025 klo 14.00Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design
Regulatoriskt pressmeddelande25.06.2025 klo 14.00The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2
Regulatoriskt pressmeddelande19.06.2025 klo 14.40Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2
Regulatoriskt pressmeddelande17.06.2025 klo 19.47Update regarding large shareholder’s exercise of warrants of series TO 2
Regulatoriskt pressmeddelande17.06.2025 klo 09.30Diagonal Bio expands equine panel with addition of strangles
Regulatoriskt pressmeddelande13.06.2025 klo 09.00Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025
Pressmeddelande11.06.2025 klo 12.30Diagonal Bio shares progress update on LAMPlify® commercial pilots
Regulatoriskt pressmeddelande09.06.2025 klo 15.00Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2